Marilyn Fernandez of Altor Bioscience Corporation in the U.S. will engineer single chain T cell receptors (TCR) to deliver immunotherapies to HIV-infected cells. These TCRs will be engineered to recognize known viral variants to linked to the emergence of drug-resistant HIV mutations.
Grant ID
OPP52092
Show on Hub
On
Show on Spoke
On
Follow-on Funding
Off
Lead Funding Organization
Initiatives
Principal Investigator
Award Manager
Individual Funder Information
Funding Organization
Funding Amount (in original currency)
100000.00
Funding Currency
USD
Funding Amount (in USD)
100000.00
Project Type
Project Primary Sector
Project Subsector
Funding Date Range
-
Funding Total (In US dollars)
100000.00
Co-Funded
False